address1,address2,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,earningsCallTimestampStart,earningsCallTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,shortName,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,regularMarketChangePercent,regularMarketPrice,marketState,longName,hasPrePostMarketData,firstTradeDateMilliseconds,sourceInterval,exchangeDataDelayedBy,cryptoTradeable,trailingPegRatio
The Gamma Building,Ideongatan 1,Lund,223 70,Sweden,46 4 62 86 85 50,https://www.bioinvent.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"BioInvent International AB (publ), a clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.",118,"[{'maxAge': 1, 'name': 'Dr. Martin  Welschof Ph.D.', 'age': 63, 'title': 'President & CEO', 'yearBorn': 1961, 'fiscalYear': 2024, 'totalPay': 5097000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stefan  Ericsson M.B.A.', 'age': 61, 'title': 'Chief Financial Officer', 'yearBorn': 1963, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Marie  Moores M.Sc., R.G.N.', 'age': 56, 'title': 'Chief Operating Officer', 'yearBorn': 1968, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kristoffer Rudenholm Hansson', 'age': 50, 'title': 'Senior Vice President of Technical Operations', 'yearBorn': 1974, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Björn  Frendéus', 'age': 51, 'title': 'Chief Scientific Officer', 'yearBorn': 1973, 'fiscalYear': 2024, 'totalPay': 2353000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cecilia  Hofvander', 'age': 57, 'title': 'Vice President of Investor Relations', 'yearBorn': 1967, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andres  McAllister', 'age': 68, 'title': 'Chief Medical Officer', 'yearBorn': 1956, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Ingrid  Teige', 'title': 'Head of Preclinical Research', 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sylvie  Ryckebusch', 'age': 59, 'title': 'Chief Business Officer', 'yearBorn': 1965, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ingunn Munch Lindvig', 'age': 59, 'title': 'Senior Vice President of Regulatory Affairs', 'yearBorn': 1965, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,2,35.6,35.0,35.0,36.4,35.6,35.0,35.0,36.4,0.0,-0.049,-9.109414,51745,51745,98979,69181,69181,35.6,35.75,0,0,2372247552,22.7,50.8,39.014664,35.264,34.80825,0.0,0.0,SEK,False,1539938304,0.0,30820789,65804400,0.0,0.05244,66263900,11.697,3.0606139,1735603200,1767139200,1743379200,-468060992,-7.16,-3.93,1:25,1607904000,25.326,-3.126,-0.08087289,0.11729753,EQUITY,35.8,100.0,85.0,92.5,92.5,none,2,742208000,11.279,-492655008,15186000,9.322,9.411,60804000,1.973,0.925,-0.28767002,-0.46750998,60804000,-315793120,-434566016,2.713,1.0,0.0,-5.5663204,SEK,BINV.ST,en-US,US,Equity,Delayed Quote,True,HIGH,-8.08729,1756188000,1756188000,1756188000,1740668400,1740668400,False,-7.16,-3.93,9.73701,3.6766932,0.5359993,0.0151996175,0.9917488,0.028491775,BioInvent International AB,0.20000076,35.0 - 36.4,Stockholm,98979,13.099998,0.5770924,22.7 - 50.8,-15.0,-0.2952756,[],1752593396,STO,finmb_139682,Europe/Stockholm,CEST,7200000,se_market,False,0.5617999,35.8,PREPRE,BioInvent International AB (publ),False,992329200000,15,0,False,
